Salvage therapy for Hodgkin's lymphoma

Cancer Journal

Volumn 15, Issue 2, 2009, Pages 161-163

  Quddus, Fahd ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplant; Hodgkin's lymphoma; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MALPHALAN; MDX 060; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PREDNISONE; PROCARBAZINE; SGN 30; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ALLOTRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; LYMPH NODE IRRADIATION; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HODGKIN DISEASE; HUMANS; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 68049131240     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181a1438a     Document Type: Review

References (31)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30; erratum in CA Cancer J Clin. 2005;55:259.
2. Glaser SL, Jarrett RF. The epidemiology of Hodgkin's disease. Baillieres Clin Haematol. 1996;9:401-416.
3. Oza AM, Ganesan TS, Leahy M, et al. Pattern of survival in patients with Hodgkin's disease: long follow up in a single center. Ann Oncol. 1993;4:385-392. (Pubitemid 23193103)
4. Horning SJ. Hodgkin's disease. In: Cavalli F, Hansen HH, Kaye SB, eds. Textbook of Medical Oncology. 2nd ed. London, England: Martin Dunitz; 2000:461-474.
5. Diehl V, Mauch PM, Harris NL. Hodgkin's disease. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. vol 2. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001: 2339-2387.
6. Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program. 2006;259-265.
7. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
8. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433. (Pubitemid 29323856)
9. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 1997;38:343-348. (Pubitemid 27376879)
10. Hutchings A, Loft A, Hansen M, et al. FDG-PET after 2 cycles of chemotherapy predicts treatment failure and progression free survival in Hodgkin's lymphoma. Blood. 2005;108:52.
11. Fallanca F, Giovacchini G, Ponzoni M, et al. Cervical thymic hyperplasia after chemotherapy in an adult patient with Hodgkin's lymphoma: a potential cause of false-positivity on [18F]FDG PET/CT scanning. Br J Haematol. 2008;140:477. (Pubitemid 351230068)
12. Longo DL, Puffey PL, Young RC, et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210-218.
13. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol. 2002;20:221-230. (Pubitemid 34032615)
14. Uematsu M, Tarbell N, Silver B, et al. Wide field radiation therapy with or without chemotherapy for patients with Hodgkin's disease in relapse after initial combination chemotherapy. Cancer. 1993;72:207-212. (Pubitemid 23182074)
15. Brada M, Eeles R, Ashley S, et al. Salvage radiotherapy in recurrent Hodgkin's disease. Ann Oncol. 1992;3:131-135.
16. Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys. 1997;39:599-607. (Pubitemid 27441426)
17. Pezner RD, Lipsett JA, Vora N, et al. Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval. Int J Radiat Oncol Biol Phys. 1994;30:965-970. (Pubitemid 24355949)
18. Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol. 1994;12:580-586. (Pubitemid 24079902)
19. Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995;6:543-549.
20. Rodriguez J, Rodriquez MA, Fayad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999;93:3632-3636. (Pubitemid 29249808)
21. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:528-534. (Pubitemid 27074219)
22. Bonadonna G, Santoro A, Gianni AM, et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol 1991;2(Suppl 1):9-16.
23. Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984;101:440-446. (Pubitemid 14018037)
24. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. 1999;10:593-595. (Pubitemid 29305439)
25. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310-4316. (Pubitemid 35429668)
26. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplant in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32:673-679. (Pubitemid 37258622)
27. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II sudy. J Clin Oncol. 2000;18:2615-2619. (Pubitemid 30432529)
28. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: a new promising drug in Hodgkin's disease. Leuk Lymphoma. 1996;22:409-414. (Pubitemid 26341006)
29. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin's lymphoma: results of a large multicenter study of the German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol. 2005;16:116-123. (Pubitemid 40124488)
30. Ansell S, Byrd J, Horwitz S, et al. Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's disease and anaplastic large cell lymphoma. Blood. 2003;102 (11, pt 1):181a (abstract 632).
31. + hematologic malignancies. Blood. 2003;102 (11, pt 1):647a (abstract 2390).